Role of systemic peri-operative chemotherapy in management of transitional cell carcinoma of bladder

Rishi Nayyar, Narmada P. Gupta

Department of Urology, Dr RML Hospital and PGIMER, New Delhi. Academic & Research, Medanta Institute of Kidney and Urology, Medanta - The Medicity, Gurgaon, Formerly Professor and Head, Department of Urology All India Institute of Medical Sciences, New Delhi, India

ABSTRACT

Bladder cancer has variable biological behavior pattern in different individuals and the debate regarding peri-operative use of systemic chemotherapy with the surgical management remains. The optimal treatment strategy, regimen and the timing of peri-operative chemotherapy are not yet known. Here we review the existing literature for the use of systemic peri-operative chemotherapy in management of advanced bladder cancer.

Key words: Bladder cancer

INTRODUCTION

Bladder cancer is among the common urological cancers, being second only to prostate cancer in terms of prevalence among middle aged and elderly men.[1] It is more common in men than women (3:1).[2] About 20-30% of cases present with invasive tumors at diagnosis. Mortality from bladder cancer is also high. Approximately 5000 deaths have been reported to occur per year in UK.[3] Although radical cystectomy provides excellent long-term progression-free survival, recurrences remain a concern particularly for cases with higher stage and grade of disease. Overall 5-year survival rates after cystectomy fall from 50 to 60% for stage T1-T2 to 26-44% for stage pT3b-4 and 13-29% for stage N2-N3.[4] Micrometastasis, both regional and distant, has been considered as an important factor leading to local or distant failure. A report evaluating long-term outcomes after radical cystectomy in patients with T3a and T3b disease showed local and distant recurrence to occur in 9 and 29% of patients, respectively.[5] It is this relatively high incidence of distant failure which implies a potential role for early peri-operative chemotherapy in management of bladder cancer by eradicating the synchronously existing micrometastasis. This theoretical potential to impart survival benefits is similar to the proven role of peri-operative chemotherapy in other visceral tumors like breast, lung and colon cancer. Here we review the existing literature concerning the use, problems and outcomes with the use of systemic peri-operative chemotherapy in management of operable localized or locally advanced bladder cancer.

CHEMOTHERAPY REGIMENS, REPORTED EFFICACIES AND TOXICITIES

Bladder cancer is a reasonably chemosensitive tumor and as many as 40-70% of cases show some response to chemotherapeutic drugs initially. Several drugs have been used in the past in different clinical settings for treatment of bladder cancer. Single agent therapies have been used, most commonly cisplatin and methotrexate, with limited efficacy and response rates ranging from about 5 to 50%.[6] Combination chemotherapy using multiple drugs has been shown to be superior to the use of single agents in sequential manner.[7,8] Methotrexate, vinblastine, Adriamycin and cisplatin (MVAC) regimen, first developed by Sternberg et al.,[9] has repeatedly shown survival benefits in several randomized trials and is currently considered the standard to compare efficacy of newer regimens.[8,10] A 14% overall survival advantage
was shown at 5 years in patients receiving neoadjuvant MVAC (57%) compared to those receiving cystectomy alone (43%).[10] This regimen is, however, significantly toxic and may not be tolerated well by many. Cisplatin, methotrexate and vinblastine (CMV) regimen though less toxic and better tolerated is considered to be less efficacious,[11,12] though no head to head direct comparative trials are available. The most significant side effects (grade 3 and 4) include myelosuppression, mucositis, alopecia, nausea, vomiting, infection and diarrhea, which occur frequently enough to merit dose adjustment, or withholding chemotherapy. Only 37% of cycles of chemotherapy were given without needing dose adjustment in one phase III study.[13]

Strategy using dose escalation has been tried to good effect with the availability of recombinant hematopoietic growth factors. High-dose MVAC with granulocyte colony-stimulating factor (GCSF) showed improved overall response rates of 61% (95% CI 54–70%) versus 50% (95% CI 42–59%) for standard MVAC, at comparable toxicity.[14] Other combinations have also been tried in an effort to search less toxic combinations with equal or better efficacy. Gemcitabine and cisplatin (GC) has shown statistically equal response rates and disease free or overall survival times compared to MVAC regimen for patients with advanced bladder cancer, though with lower toxicity and lower treatment-related morbidity and mortality.[15] Presently as per 2010 NCCN guidelines, it is considered as the standard of care ahead of MVAC therapy, which remains a relatively cheaper option.

A host of other chemotherapeutic agents and regimens have been assessed[6] in various clinical settings, but none has demonstrated improved response seen consistently with other standard regimens.

**NEoadjuvant versus ADjUVANT CHEMOTHERAPY**

Neoadjuvant therapy refers to systemic chemotherapy when given before a planned radical surgery to be done with a curative intent. It targets to kill micro-metastatic deposits which remain undetermined on present day imaging modalities. Its purported advantages include dealing with micro-metastasis early without any further delay, while waiting for surgery and its outcome. The patient is also in best physiological frame to tolerate the side effects of chemotherapeutic drugs, since radical cystectomy entails a major anatomical resection and alteration in physiological and biochemical milieu of the patient. Also, the response to chemotherapy can be clinically gauged better than in the adjuvant setting, using in vivo decrease in size of the bladder lesion before the surgery as a surrogate marker to the chemosusceptibility of the tumor.[15] It is not presently clear as to what percentage of bladder tumors is chemoresistant at presentation and to what drugs. At best, the reported pathological complete response rates of various regimens in neoadjuvant setting are not more than 14-38% and overall response rates not more than 30-65% when used in adjuvant setting.[16,17]

The clinical response of the disease to chemotherapy regimen used in neoadjuvant setting may be used as a benchmark for the use of same or different regimen in the post-op period as adjuvant therapy. Although rare and unproven, neoadjuvant therapy also has the potential of bladder preservation in cases that show complete response. Availability of the tumor tissue biopsy both before and after the chemotherapy is also helpful for research purposes in developing molecular or biological markers to grade chemosensitivity of tumors.[17]

Potential disadvantages of giving chemotherapy before the surgery include delaying the definitive surgical treatment of the locoregional disease by 3 or more months, more so because the biological response of the tumor to the chemotherapy is unknown when the neoadjuvant chemotherapy is to be planned. Whether delay in surgery, in cases that turn out to have chemoresistant tumors, ultimately has any deleterious effect over long-term outcomes is not known. However, some studies do suggest delaying surgery results in poorer outcomes for patients of carcinoma bladder.[18–20] Extrapolating these findings, it seems logical that methods be devised to preoperatively identify that subgroup of cases who are chemoresistant, so that alternative regimens are planned in those cases at the outset. Moreover, the presently available chemotherapy regimens have associated toxicities in a significant proportion of patients, becoming an aversive factor for many clinicians to use neoadjuvant chemotherapy. Besides, neoadjuvant therapy is planned based on clinical staging rather than pathological staging. Therefore, some patients may be subjected to overtreatment and undue toxicity of drugs. Staging errors to the tune of 30% have been reported in literature. However, as of now, neoadjuvant treatment has not been shown to increase morbidity or recovery from surgery.

The Medical Research Council and European Organization for Research and Treatment of Cancer (MRC/EORTC) conducted a large randomized multi-institutional trial using CMV as three cycles of neoadjuvant therapy in T2G0, T3, T4a, N0–N1, and M0 disease.[21] Local treatment–included radical cystectomy and/or radiotherapy. This trial showed only a 5.5% (non-significant, P=0.075) survival difference at 3 years favoring the chemotherapy arm (55.5%) compared to non-chemotherapy arm (50%). Although small, this difference in survival has been shown to be maintained even at longer follow up of 5 and 8 years (50% versus 44% and 43% versus 37%, respectively) and even attained statistical significance.[22] Statistically significant differences in favor of neoadjuvant chemotherapy have also been reported by the Grossman group using MVAC,[10] and Abol Enein group using carboplatin and MV for T2–4 disease.[23] There are other several trials which have shown benefit in the chemotherapy
arm compared to only local treatment though the difference did not reach level of significance.\(^{24-26}\) A meta-analysis of various studies comprising more than 2600 patients with high-risk bladder cancer showed a significantly improved (5%) overall survival at 5 years (\(P=0.016\)) regardless of the type of local treatment used.\(^{27}\) Thus to say, present literature does favor the use of neoadjuvant chemotherapy in high-risk patients undergoing radical cystectomy.

Chemotherapy is also given preoperatively in cases with advanced loco-regional disease to down-stage the disease so as to achieve negative surgical margins. Neoadjuvant therapy has also been tried together with preoperative radiation therapy.

Adjuvant chemotherapy refers to use of chemotherapeutic agents as an adjunct after radical surgery with curative intent. Its advantages include availability of detailed pathological staging for better prognostication of disease. Also chemotherapeutic drugs have less disease burden to counter after the surgery. It is suggested that increased turnover of the tumor cells in a patient recovering from a major surgery may make the tumor cells more susceptible to chemotherapeutic drugs. Such treatment approach may be associated with less patient anxiety since major tumor burden had already been removed during the surgery itself. This approach was used during early phase of development of chemotherapy for bladder cancer, use being mostly limited to pathologically locally advanced or metastatic disease. However, there are not many well-constructed randomized studies with large number of cases in the adjuvant setting.\(^{28,29}\) Only few randomized trials have been done using this approach comparing the response to a control arm, and very few have demonstrated clinically significant overall survival advantage.\(^{30}\) or improved disease-free survival.\(^{30-32}\) Still, this approach is widely used currently especially for locally advanced or node-positive disease after radical local therapy (cystectomy or radiotherapy), given the inhibition of urologists to use neoadjuvant treatment, and definitive trend of improved survival in most available studies especially for node-positive disease. A summary of survival results from some major randomized studies of neoadjuvant and adjuvant chemotherapy is given in Table 1.

### CLINICAL DECISION MAKING AND CURRENT STANDARDS

Radical cystoprostastectomy with regional lymphadenectomy is currently the standard choice treatment for operable clinically organ confined muscle-invasive bladder cancer in males. In females anterior exenteration is its standard counterpart operation. It provides cure in many but disease recurrence is known to occur in as many as 30-50% over the long term.\(^35\) A 73% recurrence-free survival at 5 years

#### Table 1: Table depicting survival results from various randomized trials of neoadjuvant and adjuvant chemotherapy in cases of muscle-invasive bladder cancer

| Study                        | Number of cases | Type of local therapy | Chemotherapy regimen used | Survival benefit from chemotherapy | Other remarks                                      |
|------------------------------|-----------------|------------------------|---------------------------|-----------------------------------|--------------------------------------------------|
| **Selected randomized trials of neoadjuvant chemotherapy**                      |                 |                        |                                          |                                                  |
| Hall, 2002 (MRC/EORTC trial)\(^{21}\)                                      | 976             | Cystectomy ± radiation | CMV                        | 15% at 7 years                       |                                                  |
| Grossman, 2003\(^{22}\)                                                    | 317             | Cystectomy             | MVAC                      | 14% at 5 years                      |                                                  |
| Malmstrom, 1996 (Nordic I)\(^{33}\)                                       | 325             | Cystectomy ± radiation | Cisplatin + Adriamycin     | 15% at 5 years for \(T_3\) and \(4a\)   |                                                  |
| Sheriff, 2002 (Nordic II)\(^{24}\)                                        | 317             | Cystectomy             | Cisplatin + Methotrexate   | No significant difference at 5 years   |                                                  |
| **Selected randomized trials of adjuvant chemotherapy**                     |                 |                        |                                          |                                                  |
| Skinner, 1991\(^{30}\)                                                    | 91              | Cystectomy             | Cisplatin + Cyclophosphamide + Adriamycin (CISCA) | Significant improvement in time to progression and median survival time | Long accrual time, statistically underpowered   |
| Stockle, 1995\(^{31}\)                                                    | 49              | Cystectomy             | MVAC or Methotrexate + Vinblastine + Epirubicin + Cisplatin (MVEC) | Significant improvement in relapse free survival at 2 years | Not designed to deduct overall survival, non-chemotherapy arm fared very poorly than usual raising selection bias issues |
| Studer, 1994\(^{34}\)                                                    | 77              | Cystectomy             | Cisplatin                 | No significant difference at 5 years    |                                                  |
| Friela, 1996\(^{32}\)                                                    | 55              | Cystectomy             | CMV                       | Significant improvement in progression free survival | No significant difference in overall survival at 5 years |
has been reported for organ-confined disease.\textsuperscript{[36]} Since the majority of recurrences are distant, it is likely that many patients undergoing cystectomy for localized carcinoma have occult metastasis either pre-existing before the surgery which remains unidentified or develop micro-metastasis during handling of malignant tissues at the time of surgery itself. These may later on present as failure of surgery with disease recurrences. To improve upon the results of radical cystectomy, preoperative radiation therapy and peri-operative chemotherapy has been tried. Preoperative radiation therapy was routinely applied three decades earlier with the proposition of downstaging non-resectable disease, treat local micrometastasis and reduce local recurrence rates. However, improvement of disease specific survival has not been demonstrated with it.\textsuperscript{[37-39]} Chemotherapy has since been used more extensively and has shown good response rates with demonstrable survival benefits in several studies.\textsuperscript{[10,33,46]} It aims to impart long-term survival benefits compared to radical local therapy alone (radical surgery or radiotherapy).

**Organ confined bladder cancer (T\textsubscript{1} and below)**

There are very few studies which have evaluated the role of peri-operative chemotherapy in the setting of T2 disease. Existing evidence from available literature suggests no survival advantage in the Nordic cystectomy I trial,\textsuperscript{[43]} which used the neoadjuvant approach. Since all trials using the adjuvant approach have also focused upon advanced stages of bladder cancer, there is as yet no concrete support in literature for this approach as well in pT2 disease. Since it is presently not possible to conclusively foretell which cases will have positive nodes on subsequent radical cystectomy and lymphadenectomy, current NCCN guidelines 2010 suggest the use of neoadjuvant therapy. However, the same guidelines do not suggest the use of adjuvant chemotherapy if the pathological stage shows pT\textsubscript{1}N\textsubscript{0} disease.

**Extravesical bladder cancer (T\textsubscript{3a} and/or N\textsubscript{1} and above)**

Trials using adjuvant chemotherapy based on pathological staging after cystectomy have been few, not well designed and used variable chemotherapy protocols and drugs to derive consistent observations for clinical recommendations. Millikan et al. conducted a large randomized trial comparing pre-versus postoperative MVAC with post operative adjuvant MVAC chemotherapy for patients clinically staged as T\textsubscript{3a} or T\textsubscript{4} disease, or lymphovascular permeation at cystoscopic biopsy.\textsuperscript{[41]} No significant difference was found in overall survival of the two groups. However, 40% of the cases in group receiving neoadjuvant chemotherapy group showed no evidence of muscle-invasive disease at radical cystectomy. This finding further consolidates the evidence in favor of neoadjuvant chemotherapy compared to adjuvant chemotherapy, and also is comparable to findings from the neoadjuvant MRC/EORTC and SWOG 8710 trials.\textsuperscript{[21,42]} 2010 NCCN guidelines strongly suggest the routine use of neoadjuvant chemotherapy in clinical T\textsubscript{3a} or N\textsubscript{1} disease.

Based on the risk adjuvant chemotherapy is suggested if neoadjuvant treatment was not used. It goes on to consider biopsy of nodes if there is no other evidence of metastasis. If the nodes turn out to be pathologically positive for metastasis, they suggest the use of primary chemotherapy with or without radiotherapy, and consider further treatment based upon the response to primary chemotherapy.

**Locally advanced inoperable bladder cancer (T\textsubscript{4b} and/or N\textsubscript{2} and above)**

As per NCCN guidelines 2010, chemotherapy is used as the first-line treatment for cases with clinical stage T\textsubscript{4b} and above. Based upon the response to the chemotherapy further treatment may include radical cystectomy, radiotherapy, palliative TURBT or alternative chemotherapy.

**Chemotherapy in cases that cannot tolerate toxicity of combination regimens**

Patients with poor renal reserve, uncorrectable obstructive uropathy, poor cardiac status, poor performance status, poor bone marrow reserve, associated comorbidities and extreme of age are poor candidates for routine standard combination regimens. Strategies that may be used in such cases include avoiding use of cisplatin, using lower dose, simultaneously using nephroprotective agents (N-acetyl cysteine, amifostine) or growth factors, or using alternative less toxic regimens or drugs.

Bladder cancer with renal insufficiency forms a special group with as many as 25-50% of cases of carcinoma bladder presenting with renal insufficiency. It is usually related to obstructive uropathy from the tumor itself, or medical renal disease related to elderly age and associated comorbidities. Renal insufficiency precludes the use of cisplatin in these patients, with the percentage of ineligibility increasing with the increasing age of the patients.\textsuperscript{[43]} Carboplatin has been tried as an alternative, though several studies done so far, do not favor carboplatin in terms of overall response rate.\textsuperscript{[44-47]} A clinical decision must be taken to weigh the risk versus benefits of the use of cisplatin in these patients. NCCN guidelines 2010 advise for considering a split dose regimen of cisplatin for cases with borderline renal function (category 2A). Carboplatin and taxane-based regimens should be considered for advanced renal failure cases.

**Chemotherapy along with radical TURBT in the setting of bladder preservation protocol**

Bladder preservation is always an option which excites the patient and clinician alike, wherever feasible. Presently, there are no head-to-head comparisons for radical surgery versus the preservation protocol in randomized fashion. Therefore, the standard of care for muscle-invasive bladder cancer remains radical surgery. Bladder preservation protocol is used only in appropriately selected cases which are either unwilling or unfit for major surgery. Chemotherapy with or without radiotherapy is used in the clinical setting.
of $T_{2\text{onc}}, N_{1,0}$ disease, in association with radical TURBT whereby the intention is to excise all possible disease including the one which has spread into the deep muscle or out of the confines of bladder wall in to the adjacent fatty tissue. There are several studies which have shown that complete response rates of 60-80%, 5-year survival of 50-60% and survival rate with intact bladder of 40-45% can be achieved with tri-modality approach with salvage cystectomy being done only if necessary later. These outcomes are quite comparable to those achieved with early radical surgical approach in most contemporary series for muscle-invasive localized bladder cancer.\cite{48-52} However, such an approach is associated with long time of treatment and also has treatment related toxicity like genitourinary and gastrointestinal toxicities from high-dose radiation or myelodepression from chemotherapy. Most of these toxicities occur within the first 2 years. Incidence of delayed high-grade toxicities is relatively low (2-6%). Cystectomy for palliation of treatment-related toxicity is also low (0-2%).\cite{48,53} The option of using neoadjuvant chemotherapy before radical TURBT is one option for better bladder preservation, which needs to be explored further with better well-designed trials in the future.\cite{54}

**Future directions and advances**

Despite the use of multimodal therapy, long-term survival outcomes remain dismal (<50% at 5 year) in patients with invasive bladder cancer.\cite{35} Initially, a good percentage of cases show good or partial response following use of chemotherapy. However, relapses are common. As many as 60-70% cases of metastatic bladder cancer show recurrence of disease within the first one year.\cite{56} Several trials with newer cytotoxic drugs are underway in various phases of development, aiming to reduce toxicity while providing same or improved survival compared to current standards. Efforts are also underway to delineate pathways involved in development of drug resistance and explore ways to bypass those resistance mechanisms.\cite{57} Specific molecular targeted drugs may thus be developed.\cite{58-60} Gene therapy directed toward p53 tumor suppressor gene has been explored in recent times with encouraging results.\cite{61,62} Meanwhile more potent regimens are surely needed. Taxanes like paclitaxel and gemcitabine have increased the available pool of drugs to choose from, though much still remains elusive with plenty of scope for improvement. Several drugs are being investigated for potential role as second line chemotherapy.\cite{63} Various molecular markers (like p53, Bcl-2, Bax, CD40 and CD40L) have been investigated to identify patients more likely to benefit from chemotherapy. Limited success has been achieved thus far in this field.\cite{64,65}

**SUMMARY**

Chemotherapy forms an integral part of treatment of cases with bladder cancer, since surgery alone has not been able to provide long-term cure or survival especially in locally advanced cases. Present literature supports the routine use of neoadjuvant chemotherapy, either MVAC or GC regimen, in such cases. Data available for adjuvant chemotherapy is not robust enough to prove improved overall survival. Clinical assessment of the disease and detailed discussion with the patient regarding expected outcomes with or without the use of chemotherapy is warranted. Ideal cases for neoadjuvant chemotherapy would be those cases of muscle-invasive bladder tumor with good performance status, preserved renal function, and limited disease ($T_{2,0}, N_{1}$). These may be expected to gain maximum benefit out of receiving neoadjuvant therapy. As regards adjuvant therapy, ideal cases may be those who are found to have lymph node-positive disease on cystectomy specimen. Although the efficacy of adjuvant and neoadjuvant therapy are not very different, absence of conclusive evidence in favor of adjuvant therapy and possibility of determination of in vivo response with neoadjuvant chemotherapy (since pathological complete response is a powerful predictor of long-term survival) tilts the balance in favor of neoadjuvant treatment.

Overall, it is not an overstatement to say that a multimodality approach is essential to improve upon the results of radical cystectomy, particularly for patients with advanced malignancy. It is essential to properly select out cases and plan the use of peri-operative chemotherapy based on clinical setting and individual patient characteristics. It is absolutely imperative that all such administration is done under a hospital protocol in a well planned out clinical study to help improve upon the presently available evidence to this regard.

**REFERENCES**

1. Feldman AR, Kessler L, Myers MH, Naughton MD. The prevalence of cancer. Estimates based on the Connecticut Tumor Registry. N Engl J Med 1986;315:1394-7.
2. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
3. Cancer Research UK. CancerStats: Mortality, UK; 2000.
4. Khochikar MV. Treatment of locally advanced and metastatic bladder cancer. Indian J Urol 2008;24:84-94.
5. Quek ML, Stein JP, Clark PE, Daneshmand S, Miranda G, Cai J, et al. Natural history of surgically treated bladder carcinoma with extravesical tumor extension. Cancer 2003;98:955-61.
6. Chester JD, Hall GD, Forster M, Protheroe AS. Systemic chemotherapy for patients with bladder cancer – current controversies and future directions. Cancer Treat Rev 2004;30:343-58.
7. Hillcoat BL, Raghavan D, Matthews J, Keeford R, Yuen K, Woods R, et al. A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract. J Clin Oncol 1989;7:706-9.
8. Loehrer PJ Sr, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A Cooperative Group Study. J Clin Oncol 1992;10:1066-73.
9. Sternberg CN, Tagoda A, Scher HI, Watson RC, Ahmed T, Weissberg LR, et al. Preliminary results of M-VAC (methotrexate, vinblastine,
doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 1985;133:403-7.
10. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared to cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349:859-66.
11. Mead GM, Russell M, Clark P, Harland SJ, Harper PG, Cowan R, et al. A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: Results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party. Br J Cancer 1998;78:1067-75.
12. Harker WG, Meyers FJ, Freiha FS, Palmer JM, Shortliffe LD, Hannigan JF, et al. Cisplatin, methotrexate, and vinblastine (CMV): An effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J Clin Oncol 1985;3:1463-70.
13. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068-77.
14. Sterberg CN, de Mulder PH, Schornagel JH, Théodore C, Fossa SD, van Oosterom AT, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 2001;19:2638-46.
15. Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, et al. Long-term survival in metastatic transitional cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999;17:3173-81.
16. Winqquist E, Kirchner TS, Segal R, Chin J, Lukka H; Genitourinary Cancer Disease Site Group, et al. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: A systematic review and meta-analysis. J Urol 2004;171:561-9.
17. Sonpavde G, Petrylak DP. Perioperative chemotherapy for bladder cancer. Crit Rev Oncol Hematol 2006;57:133-144.
18. Hara I, Miyake H, Hara S, Gotoh A, Okada H, Arakawa S, et al. Optimal timing of radical cystectomy for patients with invasive transitional cell carcinoma of the bladder. Jpn J Clin Oncol 2002;32:14-8.
19. Lee CT, Madri R, Daignault S, Dunn RL, Zhang Y, Montie JE, et al. Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival. J Urol 2006;175:1262-7.
20. Sanchez-Ortiz RF, Huang WC, Mick R, van Arsdalen KN, Wein AJ, Malkowicz SB. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol 2003;169:110-5.
21. International Collaboration of Trialists. Neoadjuvant cisplatin, methotrexate, and vinblasteine chemotherapy for muscle-invasive bladder cancer: A randomised controlled trial. Lancet 1999;354:533-40.
22. Hall RR. International Collaboration of Trialist of the MRC. Updated results of a randomised controlled trial of neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy for muscle invasive bladder cancer. Proc Am Soc Clin Oncol 2002;21:178a.
23. Abol-Enein H, El-Baz M, Ghoneim MA. Neoadjuvant chemotherapy in the treatment of invasive transitional bladder cancer. BJU Int 1997;79:174.
24. Sengelov L, von der Maase H, Lundbeck F, Barlebo H, Colstrup H, Engelholm SA, et al. Neoadjuvant chemotherapy with cisplatin and methotrexate in patients with muscle invasive bladder tumours. Acta Oncol 2002;41:447-56.
25. Sherif A, Rintala E, Nesbit M, Holmberg L, Nilsson S, et al. Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer—Nordic cystectomy trial 2. Scand J Urol Nephrol 2002;36:419-25.
26. Italian Bladder Cancer Study Group. Neoadjuvant treatment for locally advanced bladder cancer: A randomized prospective clinical trial. J Chemother 1996;8:345.
27. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis. Lancet 2003;361:1927-34.
28. Dimopoulos MA, Moulopoulos LA. Role of adjuvant chemotherapy in the treatment of invasive carcinoma of the urinary bladder. J Clin Oncol 1998;16:1601-12.
29. Sylvestre R, Sternberg C. The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: What we do not know and why. Ann Oncol 2000;11:851-6.
30. Skinner DG, Daniels JR, Russell CA, Lieskovsky G, Boyd SD, Nichols P, et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: A prospective comparative trial. J Urol 1991;145:459-64.
31. Stöckle M, Meyenburg W, Wellek S, Voges GE, Rossmann M, Gertenbach U, et al. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: Long-term results of a controlled prospective study and further clinical experience. J Urol 1995;153:47-52.
32. Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 1996;155:495-9.
33. Malmström PU, Rintala E, Wålquist R, Hellström P, Hellsten S, Hannisdal E. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol 1995;153:1903-6.
34. Studer UE, Bacchi M, Biedermann C, Jaeger P, Kraft R, Mazzucchelli L, et al. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol 1994;152:81-4.
35. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol 2001;19:666-75.
36. Madersbacher S, Hochreiter W, Burkhard F, Thalmann GN, Danuser H, Markwalder R, et al. Radical cystectomy for bladder cancer today—a homogeneous series without neoadjuvant chemotherapy. J Clin Oncol 2003;21:690-6.
37. Smith JA Jr, Crawford ED, Paradelo JC, Blumenstein B, Hershman BR, Grossman HB, et al. Treatment of advanced bladder cancer with combined preoperative irradiation and radical cystectomy versus radical cystectomy alone: A phase III intergroup study. J Urol 1997;157:805-7.
38. Pollack A, Zagars GK, Cole CJ, Dinney CP, Swanson DA, Grossman HB. Significance of downstaging in muscle-invasive bladder cancer treated with preoperative radiotherapy. Int J Radiat Oncol Biol Phys 1997;37:41-9.
39. Cole CJ, Pollack A, Zagars GK, Dinney CP, Swanson DA, von Eschenbach AC. Local control of muscle-invasive bladder cancer: Preoperative radiotherapy and cystectomy versus cystectomy alone. Int J Radiat Oncol Biol Phys 1995;32:331-40.
40. Sánchez-Salas R, Duque Ruiz GI, Watson J, Rocha E, Barret E, Cathelineau X, et al. Comprehensive surgical and chemotherapy treatment for invasive bladder cancer. Acta Urol Esp 2009;33:1062-8.
41. Millikan R, Dinney C, Swanson D, Sweeney P, Ro JY, Smith TL, et al. Integrated therapy for locally advanced bladder cancer: Final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative MVAC. J Clin Oncol 2001;19:4005-13.
Nayyar and Gupta: Peri-operative chemotherapy in carcinoma bladder

42. Natale RB, Grossman HB, Blumenstein B, Vogelzang NJ, Trump DL, Speights VO. SWOG 8710 (INT-0080): Randomized Phase III trial of neoadjuvant MVAC + cystectomy versus cystectomy alone in patients with locally advanced bladder cancer. Proc Am Soc Clin Oncol 2001;20:2a.

43. Dash A, Galsky MD, Vickers AJ, Serio AM, Koppie TM, Dalbagni G, et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 2006;107:506-13.

44. Raabe NK, Fossa SD, Paro G. Phase II study of carboplatin in locally advanced and metastatic transitional cell carcinoma of the urinary bladder. Br J Urol 1989;64:604-7.

45. Petrosi R, Frediani B, Manganelli A, Barbanti G, De Capua B, De Lauritess A, et al. Comparison between a cisplatin-containing regimen and a carboplatin containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study. Cancer 1996;77:344-51.

46. Bellmunt J, Ribas A, Eres N, Albanell J, Almazan C, Bermejo B, et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 1997;80:1966-72.

47. Carteni G, Dogliotti L, Crucitta E, Martoni A, Siena S, Onat H, et al. Phase II randomised trial of gemcitabine plus cisplatin (GP) and gemcitabine plus doxorubicin (GC) in patients (pts) with advanced or metastatic transitional cell carcinoma of the urothelium (TCCU). Proc Am Soc Clin Oncol 2003;22:384.

48. Efstathiou JA, Bae K, Shipley WU, Kaufman DS, Hagan MP, Heney NM, et al. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol 2003;21:2247-53.

49. Ibrahim SM, Abd El-Hafeez ZM, Mohamed EM, Elsharawy IA, Kamal KM. Transurethral Resection of Bladder Tumor (TUR-BT) then Concomitant Radiation and Cisplatin Followed by Adjuvant Gemcitabine and Cisplatin in Muscle Invasive Transitional Cell Carcinoma (TCC) of the Urinary Bladder: J Egypt Natl Canc Inst 2007;19:77-86.

50. Kaufman DS, Shipley WU, Griffin PF, Heney NM, Althausen AF, Efid JT. Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med 1993;329:1377-82.

51. Rödel C, Grabenbauer GG, Kühn R, Papadopoulos T, Dunst J, Meyer M, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: Long-term results. J Clin Oncol 2002;20:3061-71.

52. Kaufman DS, Winter KA, Shipley WU, Heney NM, Wallace HJ 3rd, Toonkel LM, et al. Phase I-II RTOG study (99-09) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology 2009;73:833-7.

53. Rödel C, Weiss C, Sauer R. Organ preservation by combined modality treatment in bladder cancer: The European perspective. Semin Radiat Oncol 2005;15:28-35.

54. Shipley WU, Winter KA, Kaufman DS, Lee WR, Heney NM, Tester WR, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: Initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 1998;16:3576-83.

55. Juffs HG, Moore MJ, Tannock IF. The role of systemic chemotherapy in the management of muscle-invasive bladder cancer. Lancet Oncol 2002;3:738-47.

56. Vaughn DJ, Malkowicz SB. Recent advances in bladder cancer chemotherapy. Cancer Invest 2001;19:77-85.

57. Muramaki M, So A, Hayashi N, Sowery R, Miyake H, Fujisawa M, et al. Chemosensitization of gemcitabine-resistant human bladder cancer cell line both in vitro and in vivo using antisense oligonucleotide targeting the anti-apoptotic gene, clusterin. BJU Int 2009;103:384-90.

58. Knowles MA. What we could do now: Molecular pathology of bladder cancer. Mol Pathol 2001;54:215-21.

59. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37:59-15.

60. Youssef RF, Mitra AP, Bartsch Jr G, Jones PA, Skinner DG, Cote RJ. Molecular targets and targeted therapies in bladder cancer Management. World J Urol 2009;27:9-20.

61. Kuball J, Wen SF, Leisssner J, Atkins D, Meinhardt P, Quijano E, et al. Successful adenovirus mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. J Clin Oncol 2002;20:957-65.

62. Pagliaro LC, Keyhani A, Williams D, Woods D, Liu B, Perrotte P, et al. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: A phase I study of p53 gene therapy. J Clin Oncol 2003;21:2247-53.

63. Gallagher DJ, Milowsky MI, Bajorin DF. Advanced bladder cancer: Status of first-line chemotherapy and the search for active agents in the second-line setting. Cancer 2008;113:1284-93.

64. Hussain SA, James ND. The systemic treatment of advanced and metastatic bladder cancer patients with locally advanced bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: Initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 1998;16:3576-83.

65. Duggan B, Williamson K. Molecular markers for predicting recurrence, progression and outcomes of bladder cancer (do the poster boys need new posters?). Curr Opin Urol 2004;14:277-86.